Results 141 to 150 of about 5,687 (195)

Advancements in research on the cardiovascular toxicity caused by TEC family kinases inhibitors. [PDF]

Front Pharmacol
Zhang Y, Fu H, Kang X, Qiu Z, Yan H, He Q, Yang B, Xu Z, Luo P.   +8 more
europepmc   +1 more source

MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma. [PDF]

Blood Adv
Ruan J, Bond DA, Shah B, Allan JN, Rutherford SC, Gribbin C, Chen Z, Bhinder B, Tam W, Rossi D, Xiang J, Hobbie B, Harbhajan M, Sahni TK, Chen GZ, Sigouros M, Inghirami G, Chen-Kiang S, Elemento O, Maddocks K, Leonard JP, Martin P.   +21 more
europepmc   +1 more source

A pharmacovigilance study of Bruton's tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase. [PDF]

Front Immunol
Qu H, Jia Y, Liu Z, Li Z, Zhao X, Wu Z, Fan G, Lou Y.   +7 more
europepmc   +1 more source

Updates in the management of newly diagnosed chronic lymphocytic leukemia. [PDF]

Hematology Am Soc Hematol Educ Program
McClellan K, Sitlinger A.
europepmc   +1 more source

When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia. [PDF]

Curr Hematol Malig Rep
Benrashid S, Woyach JA.
europepmc   +1 more source

Cumulative review of cardiac failure with acalabrutinib in the treatment of chronic lymphocytic leukemia using data from clinical trials and postmarketing experience [PDF]

Bajwa N., Corry A. J., Ghia P., Jannuru S., Kreuzbauer G., Pareek M.   +5 more
core   +1 more source

Have Fixed-Duration (FD) Regimens Delivered on Their Promise in Chronic Lymphocytic Leukemia and What Is the Future of FD Regimens? A Narrative Review. [PDF]

Adv Ther
Allan JN.
europepmc   +1 more source

Patterns of Bruton's Tyrosine Kinase Inhibitor (BTKi) Usage in B-cell Lymphomas in India: A Questionnaire-Based Study. [PDF]

Cureus
Naseem A, Pednekar A, Patil S, Barkate H.   +3 more
europepmc   +1 more source

Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting. [PDF]

Future Oncol
Shah BD, Xue M, Furnback W, Yang K.
europepmc   +1 more source

Scedosporium Brain Abscess: A Rare and Fatal Drawback of Bruton Tyrosine Kinase Inhibitor Therapy [PDF]

Busana, Tiziano Tommaso, Caironi, Pietro, Camerlo, Sofia, Dalmazzo, Matteo, Davicco, Luca, De Gobbi, Marco, Morotti, Alessandro, Nicoli, Paolo, Padrini, Melissa, Perotto, Fabio, Rosati, Giorgio   +10 more
core   +1 more source